NR 293 RUA Medication Teaching Plan

Student Name

Chamberlain University

NR-293: Pharmacology for Nursing Practice

Prof. Name:

Date

Medication Teaching Plan

Our names are Jaime Weisel and Nnamdi Omeludike, and our project focuses on the oral opioid antagonist medication known as Symproic. As of December 2018, we are students of Professor Gloria King-Hoff, enrolled in the November session of the course Pharmacology for Nursing Practice. Symproic is a medication typically prescribed to patients experiencing Opioid-Induced Constipation (OIC). According to the Journal for Managed Care and Formulary Management, “Opioid-induced constipation (OIC), new or worsening constipation occurring when initiating, changing, or increasing opioid use, represents the most common of these GI effects” (p. 601).

The primary audience for our teaching project includes adult patients diagnosed with chronic pain who are prescribed opioid analgesics for pain management. The use of Symproic in pediatric patients has not been studied or approved. The aim of our educational materials, including the brochure, is to creatively and effectively inform this audience about the complications associated with opioid use. Additionally, the materials will highlight the adverse effects of opioids, the need for Symproic to mitigate these effects, and the therapeutic benefits of the medication.

According to Naldemedine: First Global Approval, Symproic “was associated with significantly greater improvements from baseline in the frequency of bowel movements per week compared with placebo (n = 620) at all assessed time points (weeks 12, 24, 36, and 52)” (Markham, p. 925). The brochure aims to educate patients about how Symproic can alleviate OIC and improve their quality of life through consistent bowel movement regulation.

Teaching Plan Table

Heading	Details	Supporting Information
Target Audience	Adults with chronic pain prescribed opioid analgesics. Pediatric use not yet studied or approved.	Focus on patients experiencing Opioid-Induced Constipation (OIC).
Medication Focus	Symproic (Naldemedine), an opioid antagonist for managing Opioid-Induced Constipation.	Shown to significantly improve bowel movement frequency compared to placebo (Markham, 2017, p. 925).
Educational Goals	Inform patients about opioid-related complications, adverse effects, and Symproic’s therapeutic use.	Based on Naldemedine: First Global Approval and other research sources.

References

Constipation too? Ready to make a move? (n.d.). Retrieved from https://www.symproic.com

Hu, K., & Bridgeman, M. B. (2018). Naldemedine (Symproic) for the treatment of opioid-induced constipation. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 43(10), 601–627.

Kaufman, M. B. (2017). Pharmaceutical approval update. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(8), 502–504.